Cerus (CERS) Corporate presentation summary

Strategic positioning and market leadership

• Leads in pathogen reduction technologies for transfused blood components, with first-mover advantage and high barriers to entry.

• Addresses a global market exceeding $7 billion, targeting unmet needs in blood safety.

• INTERCEPT is positioned as the global standard of care for transfused blood components.

• Products are sold in approximately 40 countries, with over 20 million INTERCEPT-treated doses delivered.

Financial performance and guidance

• Achieved record Q4 2025 product revenue of $57.8 million (+14% YoY) and full-year 2025 product revenue of $206.1 million (+14% YoY).

• 2025 net loss was $15.6 million, but non-GAAP adjusted EBITDA was positive at $9.5 million.

• Operating cash flow was $4.8 million in 2025, with $82.9 million in cash and equivalents at year-end.

• 2026 product revenue guidance is $224–228 million, including $20–22 million from INTERCEPT Fibrinogen Complex (IFC).

• Achieved second consecutive year of positive operating cash flow and expects a third consecutive year of positive adjusted EBITDA in 2026.

Product portfolio and innovation

• INTERCEPT Blood System covers platelets, plasma, and cryoprecipitate, with red blood cells in late-stage development.

• IFC offers immediate, enriched fibrinogen supplementation for bleeding control, with a 5-day shelf life when thawed.

• Next-generation INT200 LED-based illumination device has CE Mark and is planned for FDA submission in mid-2026.

• INTERCEPT reduces transfusion-transmitted infections and improves product availability and operational efficiency.